Iteos Therapeutics, Inc. Stock Price, News & Analysis

iTeos Therapeutics has announced promising data on its anti-TIGIT antibody, EOS-448, presented at the AACR Annual Meeting 2022. The study revealed a decrease in TIGIT-positive cells in tumor biopsies, marking a significant treatment effect. Preclinical and clinical data demonstrate EOS-448's ability to reduce suppressive immune cell populations, indicating effective engagement of FcγR. These findings support ongoing clinical trials aimed at developing EOS-448 as a potent immuno-oncology therapy for patients with advanced cancers.

iTeos Therapeutics (ITOS) has made significant strides in its immuno-oncology pipeline, reporting a cash position of $848.5 million as of December 31, 2021, ensuring funding through 2026. The company is advancing its clinical trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an A_2A receptor antagonist, in collaboration with GSK. Key initiatives include multiple registration-directed trials and triplet regimen studies, signaling robust clinical development plans. In 2021, iTeos reported a net income of $214.5 million, an improvement from a net loss the previous year.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. The presentation will focus on the company's innovative immuno-oncology therapies. A live webcast will be available on their website, with an archived replay accessible for 30 days. iTeos is advancing multiple clinical-stage programs, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Michel Detheux, will participate in two investor conferences on February 17, 2022. The 11th Annual SVB Leerink Global Healthcare Conference at 12:00 p.m. ET and Citi’s 2022 Virtual Immuno-Oncology Summit at 1:30 p.m. ET are the events scheduled for the same day. The company focuses on developing advanced immuno-oncology therapeutics, including its leading product candidates EOS-448 and inupadenant. A live webcast will be hosted on its website, with recordings available for 30 days.

iTeos Therapeutics (Nasdaq: ITOS) announced its clinical development plan for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A_2A receptor antagonist. The company is progressing with 11 clinical studies, including three planned registration-directed trials. EOS-448 is being investigated in combination therapies with anti-PD-1 agents, while inupadenant is evaluated with chemotherapy and pembrolizumab. Yvonne McGrath has been promoted to chief scientific officer, crucial for advancing iTeos’s immunotherapy pipeline targeting difficult-to-treat cancers.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the 40th Annual J.P. Morgan Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will focus on the company's advancements in immuno-oncology therapeutics. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event. iTeos is developing innovative therapies, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing anti-cancer responses.

iTeos Therapeutics (NASDAQ: ITOS) will replace Magellan Health (NASDAQ: MGLN) in the S&P SmallCap 600, effective January 5, 2022. This change coincides with Centene Corp. (NYSE: CNC) acquiring Magellan Health, pending final conditions. The adjustment is significant for iTeos as inclusion in a prominent index like the S&P SmallCap 600 can potentially improve market visibility and investor interest. This strategic move highlights the dynamic shifts within the healthcare sector as companies adapt to evolving market conditions.

iTeos Therapeutics (NASDAQ: ITOS) presented preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the ASH Annual Meeting and the TIGIT Therapies Digital Summit. The results demonstrate EOS-448's potential as a single agent and in combination with immunomodulatory drugs in treating multiple myeloma. Evidence highlights its multifaceted mechanism of action, including the activation of immune cells and depletion of immunosuppressive cells. The company is optimistic about progressing clinical trials in 2022 to improve outcomes for patients with advanced cancers.

MPM Capital has appointed Detlev Biniszkiewicz, Ph.D., as a Managing Director and Investment Committee member. His leadership and scientific expertise have contributed significantly to MPM and its portfolio, including launching several companies such as NextPoint Therapeutics. Biniszkiewicz has been with MPM since 2018 and serves on the board of iTeos Therapeutics (NASDAQ: ITOS). MPM Capital is a leading biotech investment firm focused on transforming scientific innovations into impactful therapies.